<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571218</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10054</org_study_id>
    <nct_id>NCT02571218</nct_id>
  </id_info>
  <brief_title>AF Substrate Mapping and Guided Ablation</brief_title>
  <official_title>Substrate-Targeted Catheter Ablation to Treat Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to identify and characterize, by means of an EnSite
      Velocity Research Software, the electrophysiological characteristics of substrates that
      sustain AF in patients with persistent AF and to test whether ablation of such
      patient-specific substrates might improve the acute and long-term success of conventional
      catheter ablation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single center, randomized, single-blind, controlled, 2-arm
      parallel group trial in Milan, Italy.

      The total duration of the study is expected to be 24 months with ~12 months of enrollment.

      Approximately 80 subjects suffering from persistent AF will be randomized in a 1:1 fashion to
      the following investigation arms:

        -  Modified circumferential pulmonary vein ablation alone (mCPVA);

        -  Substrate-targeted ablation guided by AF substrate mapping, followed by completion of
           modified circumferential pulmonary vein ablation (Substrate+ mCPVA)

             -  Ablate the areas that have fast and regular electrical activities, starting from
                the fastest cycle length (defined by Mean CL in the range of 120-250 milliseconds,
                and SD CL in the range of 1-30 milliseconds

             -  Ablate the areas that have consistent rotational or focal propagation pattern
                (defined by conduction velocity vectors)

             -  Ablate the areas that comprises the slow conduction zone of possible arrhythmia
                circuits

             -  If AF terminates during RF ablation, stimulation protocol will be used to examine
                if AF is re-inducible. If AF sustains or is re-inducible and physician decides to
                remap, mapping will be performed again for substrate-targeted ablation. If AF is
                not re-inducible, mCPVA will be completed

      Subjects will be followed up at 3, 6, 12 months.

      The primary objective of the study is to assess acute and long-term outcome of
      patient-tailored substrate-targeted ablation (Substrate) plus modified circumferential
      pulmonary vein ablation (Substrate+mCPVA) versus modified circumferential pulmonary vein
      ablation alone (mCPVA). The secondary objective of the study is to map and characterize
      electrophysiological substrates during AF, including regular and fast activities, complex
      fractionated electrograms, wave front propagation directions, and fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Clinical Success Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from symptomatic AF off antiarrhythmic drug therapy assessed from the end of the 3 months blanking period to 12 months following the ablation procedure, documented by implantable loop recorder (ILR) monitoring or trans-telephonic (TT) ECG monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Ablation Procedure Outcome</measure>
    <time_frame>During Ablation</time_frame>
    <description>Acute AF termination or significant AF cycle length slowing during RF application in ablation procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>mCPVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substrate+mCPVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Substrate+mCPVA</intervention_name>
    <description>The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
    <arm_group_label>Substrate+mCPVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mCPVA</intervention_name>
    <description>The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
    <arm_group_label>mCPVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 85 years of age

          -  Persistent AF scheduled to undergo catheter ablation with approved standard indication
             by ESC/EHRA guidelines

          -  First or second time ablation for persistent AF

          -  Ability to provide written informed consent for study participation and be willing and
             able to comply with the study evaluations and follow up schedule

        Exclusion Criteria:

          -  Had two or more previous AF ablation procedures

          -  Secondary AF

          -  Hyperthyroidism

          -  Left ventricular ejection fraction &lt;30%

          -  NYHA functional class IV

          -  Left atrial area &gt; 35 cm2

          -  Uncorrected severe valvular heart disease

          -  Contraindication to anticoagulation

          -  Presence of left atrial thrombus

          -  Recent (&lt;6 Months) myocardial Infarction or unstable angina or coronary artery by-pass

          -  Thoracic surgery for congenital, valvular or aortic disease

          -  History of cerebrovascular accidents

          -  Pregnancy

          -  Significant comorbidities such as cancer, severe renal insufficiency requiring
             hemodialysis, severe obstructive lung disease, cirrhosis, with a life expectancy less
             than 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.R.C.C.S. Policlinico San Donato</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <results_first_submitted>April 3, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>mapping</keyword>
  <keyword>substrate</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02571218/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>mCPVA</title>
          <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.
mCPVA: The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
        </group>
        <group group_id="P2">
          <title>Substrate+mCPVA</title>
          <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
Substrate+mCPVA: The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>mCPVA</title>
          <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.
mCPVA: The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
        </group>
        <group group_id="B2">
          <title>Substrate+mCPVA</title>
          <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
Substrate+mCPVA: The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="10.8"/>
                    <measurement group_id="B2" value="63.5" spread="10.4"/>
                    <measurement group_id="B3" value="61.7" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertenstion, n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus, n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years AF diagnosed, y</title>
          <units>years</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="5.4"/>
                    <measurement group_id="B2" value="5.4" spread="5.3"/>
                    <measurement group_id="B3" value="4.5" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AF persistency, mo</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="1.8"/>
                    <measurement group_id="B2" value="5.8" spread="1.3"/>
                    <measurement group_id="B3" value="6.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricle Ejection Fraction (%)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="5.7"/>
                    <measurement group_id="B2" value="55.5" spread="7.3"/>
                    <measurement group_id="B3" value="54.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LA area, cm2</title>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="4.8"/>
                    <measurement group_id="B2" value="24.5" spread="6.1"/>
                    <measurement group_id="B3" value="24.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long-term Clinical Success Rate</title>
        <description>Freedom from symptomatic AF off antiarrhythmic drug therapy assessed from the end of the 3 months blanking period to 12 months following the ablation procedure, documented by implantable loop recorder (ILR) monitoring or trans-telephonic (TT) ECG monitoring.</description>
        <time_frame>12 months</time_frame>
        <population>Success rate of patient's undergoing radiofrequency catheter ablation during follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>mCPVA</title>
            <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.
mCPVA: The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
          </group>
          <group group_id="O2">
            <title>Substrate+mCPVA</title>
            <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
Substrate+mCPVA: The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Clinical Success Rate</title>
          <description>Freedom from symptomatic AF off antiarrhythmic drug therapy assessed from the end of the 3 months blanking period to 12 months following the ablation procedure, documented by implantable loop recorder (ILR) monitoring or trans-telephonic (TT) ECG monitoring.</description>
          <population>Success rate of patient's undergoing radiofrequency catheter ablation during follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Ablation Procedure Outcome</title>
        <description>Acute AF termination or significant AF cycle length slowing during RF application in ablation procedure</description>
        <time_frame>During Ablation</time_frame>
        <population>Success rate of radiofrequency catheter ablation to terminate atrial fibrillation during the ablation procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>mCPVA</title>
            <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.
mCPVA: The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
          </group>
          <group group_id="O2">
            <title>Substrate+mCPVA</title>
            <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
Substrate+mCPVA: The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Ablation Procedure Outcome</title>
          <description>Acute AF termination or significant AF cycle length slowing during RF application in ablation procedure</description>
          <population>Success rate of radiofrequency catheter ablation to terminate atrial fibrillation during the ablation procedure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year throughout the follow up of the study.</time_frame>
      <desc>Adverse event and or serious adverse event definition does not differ from the clinicaltrials.gov definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>mCPVA</title>
          <description>Subjects in the mCPVA arm will undergo intervention called &quot;modified circumferential pulmonary vein ablation&quot;, which is considered to be the standard ablation treatment for AF.
mCPVA: The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.</description>
        </group>
        <group group_id="E2">
          <title>Substrate+mCPVA</title>
          <description>Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
Substrate+mCPVA: The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giuseppe Ciconte</name_or_title>
      <organization>IRCCS Policlinico San Donato</organization>
      <phone>+39 02 52 77 42 60</phone>
      <email>g.ciconte@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

